{"id":"NCT00078377","sponsor":"Cephalon","briefTitle":"Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy","officialTitle":"A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CEP-10953 (150 and 250 mg/Day) as Treatment for Adults With Excessive Sleepiness Associated With Narcolepsy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-03","primaryCompletion":"2005-01","completion":"2005-01","firstPosted":"2004-02-26","resultsPosted":"2010-01-21","lastUpdate":"2013-07-19"},"enrollment":196,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Narcolepsy"],"interventions":[{"type":"DRUG","name":"Armodafinil","otherNames":[]},{"type":"DRUG","name":"Armodafinil","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to determine whether treatment with Armodafinil (CEP-10953) is more effective than placebo treatment for patients with excessive sleepiness associated with narcolepsy by measuring mean sleep latency from the Maintenance of Wakefulness Test (MWT) (20-minute version)(average of 4 naps at 0900, 1100, 1300, and 1500) and by the Clinical Global Impressions of Change (CGI-C) ratings (as related to general condition) at week 12 (or last postbaseline observation)","primaryOutcome":{"measure":"Change From Baseline in Maintenance of Wakefullness Test (MWT) Score at 12 Weeks","timeFrame":"change from baseline at 12 weeks","effectByArm":[{"arm":"Armodafinil 250 mg/Day","deltaMin":2.6,"sd":6.24},{"arm":"Armodafinil 150 mg/Day","deltaMin":1.3,"sd":6.31},{"arm":"Placebo","deltaMin":-1.9,"sd":6.87},{"arm":"Armodafinil Combined Group (250 mg/Day and 150 mg/Day)","deltaMin":1.9,"sd":6.28}],"pValues":[{"comp":"OG000 vs OG001 vs OG002","p":"0.0024"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":67},"commonTop":["Headache","Nausea","Nasopharyngitis","Dizziness","Decreased appetite"]}}